US

Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

Republic of Korea *

oncology-assessing1920

Application Note

CDK signaling in oncology: assess the effectiveness of a CDK9-targeting PROTAC molecule

CDK9 is an attractive target for cancer therapeutics due to its crucial role in transcription regulation, particularly of short-lived anti-apoptotic proteins such as MCL-1 and XIAP which are critical to the survival of cancer cells. One approach for specifically degrading CDK9 is using a proteolysis targeting chimera (PROTAC).

In this application note, you will discover:

The rapid and strong effect of CDK9 PROTAC molecule Thal-SNS-032, demonstrating specificity in CDK9 degradation
How HTRF^® and AlphaLISA^™ SureFire^® Ultra^™ are used to measure protein levels, with each tool showcasing the ability of PROTACs to rapidly degrade a targeted protein making it a unique tool in the fight against cancer

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

Have a sales representative contact me

First Name

Last Name

Country

Email Address

Company

Zip / Postal Code

Business Phone

Role

Products and Services of Interest

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

Download Resource

CDK signaling in oncology: assess the effectiveness of a CDK9-targeting PROTAC molecule

Download Application Note